SolasCure

Hydrogel
#Phase II trial #SolasCure

Gel could heal chronic wounds seven times faster, data shows 

A new gel could heal chronic wounds seven times faster than current standard of care, data suggests.  Biotechnology company SolasCure has released data from its Phase II trial of the Aurase Wound Gel (AWG), showing the gel demonstrated 22 times faster debridement and seven times faster healing compared to standard of care.  … Read More

#News

Seed fund
#Biologics / Biotechnology #Funding #Investment #SolasCure #Wound care

SolasCure secures £10.9m funding to develop Aurase Wound Gel

Biotechnology company SolasCure has completed its £10.9m ($13.3m) Series B investment round. The funding round was led by Seneca Partners and also included BRAIN Biotech, EVA Pharma, Jonathan Milner, and Wealth Club. SolasCure’s first investigational product, Aurase Wound Gel, a hydrogel containing an enzyme… Read More

#Business & Investment #News